Seme Diallo

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans

Yueh–Ming Loo, Patrick M. McTamney, Rosalinda H. Arends et al. · Science Translational Medicine · 2022 · 208 citations · Full text

Humoral Response, Immunology, Viral Pathogenesis +18

Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897

Qing Zhu, Bin Lü, Patrick M. McTamney et al. · The Journal of Infectious Diseases · 2018 · 81 citations · Full text

AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults

Yíngyún Caì, Seme Diallo, Kim Rosenthal et al. · Science Translational Medicine · 2024 · 26 citations

1355. The SARS-CoV-2 Monoclonal Antibody AZD3152 Potently Neutralizes Historical and Emerging Variants and is Being Developed for the Prevention and Treatment of COVID-19 in High-risk Individuals

Joseph R. Francica, Cai Yingyun, Seme Diallo et al. · Open Forum Infectious Diseases · 2023 · 13 citations · Full text

Viral Diagnostics, Immunodeficiencies, Immunology +20

AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans

Yueh–Ming Loo, Patrick M. McTamney, Rosalinda H. Arends et al. · 2021 · 12 citations · Full text

Viral Pathogenesis, Immunology, Immunodominance +21